Amphastar Pharmaceuticals In (AMPH) — 13F Filings Explorer (Q2 2026)

AMPH ranks #2832 out of 37501 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

214 institutions disclose a position in AMPH, but none treat it as a major bet — even Bridge City Capital, LLC, its most concentrated holder, allocates just 1.6% of its own portfolio to it.

Lsv Asset Management has added to its AMPH position for two straight quarters, increasing it by $10.0M to reach $13.0M today.

BlackRock has trimmed its AMPH position for two straight quarters, cutting it by $40.8M while still holding $105.4M.

AMPH is up 3.4% today, and institutions have been net buyers of $17.3M this quarter — today's price move and the underlying institutional flow are pointing the same direction.

AMPH posted net income of $78.5M over the trailing twelve months, and currently trades at a P/E of 14.6.

• Profitable — net income of $78.5M over the trailing twelve months
• Revenue grew 1.0% year over year
• Net income declined year over year, from $134.7M to $78.5M
• Generated $156.1M in positive operating cash flow
• Current ratio of 4.02x — enough short-term assets to cover short-term liabilities
• Liabilities run 1.07x equity — within a conventional range